Damora Therapeutics (DMRA) EBITDA (2019 - 2026)
Damora Therapeutics' (DMRA) quarterly EBITDA came in at -$30.8 million in Q1 2026, down 1085.49% YoY from $3.1 million in Q1 2025, and up 84.72% on a QoQ basis from -$201.7 million in Q4 2025.
Damora Therapeutics (DMRA) EBITDA (2019 - 2026) Analysis & Trends
Damora Therapeutics (DMRA) has 8 years of EBITDA data on file, last reported at -$30.8 million in Q1 2026.
- Quarterly EBITDA fell 1085.49% year-over-year to -$30.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$239.1 million (down 1150.57% YoY) and the FY2025 annual result came in at -$210.9 million, down 847.31% from the prior year.
- EBITDA rose to -$30.8 million in Q1 2026, from -$201.7 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$2.6 million in Q1 2025 to a low of -$201.7 million in Q4 2025.
- A 5-year average of -$21.5 million and a median of -$8.6 million in 2023 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2024 — EBITDA jumped 57.45% — and 2025, when it sank 2739.99%.
- Tracing DMRA's EBITDA over 5 years: stood at -$13.5 million in 2022, then jumped by 50.68% to -$6.7 million in 2023, then slipped by 6.46% to -$7.1 million in 2024, then slumped by 2739.99% to -$201.7 million in 2025, then surged by 84.72% to -$30.8 million in 2026.
- The last three EBITDA figures came in at -$30.8 million (Q1 2026), -$201.7 million (Q4 2025), and -$3.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | -34.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -34.99 Mn |
| Mar 31, 2026 | -30.81 Mn |
| Dec 31, 2025 | -201.70 Mn |
| Sep 30, 2025 | -3.16 Mn |
| Jun 30, 2025 | -3.42 Mn |
| Mar 31, 2025 | -2.60 Mn |
| Dec 31, 2024 | -7.10 Mn |
| Sep 30, 2024 | -3.84 Mn |
| Jun 30, 2024 | -5.58 Mn |
| Mar 31, 2024 | -5.74 Mn |
| Dec 31, 2023 | -6.67 Mn |
| Sep 30, 2023 | -8.58 Mn |
| Jun 30, 2023 | -11.16 Mn |
| Mar 31, 2023 | -13.49 Mn |
| Dec 31, 2022 | -13.53 Mn |
| Sep 30, 2022 | -13.62 Mn |
| Jun 30, 2022 | -17.12 Mn |
| Mar 31, 2022 | -16.94 Mn |
| Dec 31, 2021 | -13.47 Mn |
| Sep 30, 2021 | -12.94 Mn |